PAREXEL - Thomas Senderovitz speaks about PAREXEL's global capabilities

November 12, 2014
We are clearly seeing an increased focus on early patient access. It seems very clear to us that studies in patients already starting in first in human studies very rapidly thereafter is an increasing trend globally. The earlier you go into patients and the target populations, the earlier you can really learn about whether your potential medicine actually is effective and safe or not. Earlier access to patients and also increased use of biomarkers globally, is a clear trend that we see. PAREXEL has a unique global network of sites and expertise to address trends by accessing patients early. We have five in-house clinical Phase I units in which we can also study patients. In addition, we have world leading expertise in accessing patients out in hospitals at unique clinical sites. By doing that and utilizing our unique expertise in translational medicine and biomarkers, we can help Japanese companies in addressing these trends.
Previous Video
PAREXEL - Josef von Rickenbach speaks about the importance of the Japanese pharmaceutical market
PAREXEL - Josef von Rickenbach speaks about the importance of the Japanese pharmaceutical market

Japan's pharmaceutical market is one of the most important pharmaceutical markets in the world. It has a vi...

Next Video
PARXEL - Albert Liou speaks about drug development trends in the Asia Pacific region
PARXEL - Albert Liou speaks about drug development trends in the Asia Pacific region

I do see three major trends that are happening in the Asia Pacific region. The number one is Japan, because...